|By Business Wire||
|May 8, 2014 06:03 PM EDT||
Research and Markets (http://www.researchandmarkets.com/research/cm2s97/tnfalpha) has announced the addition of the "TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014" report to their offering.
The TNF-alpha signaling pathway stimulates the MAPK signaling module and activates NFkB.
There are today 359 companies plus partners developing 531 TNF-alpha pathway targeting drugs in 1960 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 250 drugs.
TNF-Alpha Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 247 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 243 out of the 245 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 54 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
- Includes more than 359 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Drug name & Synonyms
- Lists commercial, generic and code names for drugs.
- This Drug Pipeline Update contains 531 TNF-alpha pathway targeting drugs in development, which have a total of 1960 developmental projects in cancer. In addition there are suspended and ceased drugs.
- Included TNF-alpha pathway targeting drugs are also in development for 224 other indications, where of 140 are different cancer indications.
Pipeline Breakdown According to Number of Drugs
- Marketed # 39
- Registered # 1
- Pre-registration # 6
- Phase III # 64
- Phase II # 184
- Phase I # 234
- Preclinical # 280
- No Data # 4
- Suspended # 7
- Ceased # 250
For more information visit http://www.researchandmarkets.com/research/cm2s97/tnfalpha.
Sep. 28, 2016 04:30 PM EDT Reads: 2,796
Sep. 28, 2016 04:15 PM EDT Reads: 2,417
Sep. 28, 2016 04:15 PM EDT Reads: 1,851
Sep. 28, 2016 04:15 PM EDT Reads: 1,463
Sep. 28, 2016 04:00 PM EDT Reads: 1,479
Sep. 28, 2016 03:15 PM EDT Reads: 1,305
Sep. 28, 2016 03:15 PM EDT Reads: 4,135
Sep. 28, 2016 03:15 PM EDT Reads: 336
Sep. 28, 2016 03:00 PM EDT Reads: 3,863
Sep. 28, 2016 02:45 PM EDT Reads: 1,738
Sep. 28, 2016 02:30 PM EDT Reads: 3,313
Sep. 28, 2016 02:30 PM EDT Reads: 2,923
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
Sep. 28, 2016 02:00 PM EDT Reads: 4,419
Sep. 28, 2016 02:00 PM EDT Reads: 4,775
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lea...
Sep. 28, 2016 01:57 PM EDT Reads: 243